



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 9/28, 9/48, 31/44, 39/145, 38/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/13029</p> <p>(43) International Publication Date: 2 April 1998 (02.04.98)</p>
<p>(21) International Application Number: PCT/EP97/05234</p> <p>(22) International Filing Date: 18 September 1997 (18.09.97)</p> <p>(30) Priority Data: 96202651.4 23 September 1996 (23.09.96) EP (34) Countries for which the regional or international application was filed: NL et al.</p> <p>(71) Applicant (for all designated States except US): DUPHAR INTERNATIONAL RESEARCH B.V. [NL/NL]; C.J. Van Houtenlaan 36, NL-1381 CP Weesp (NL).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): VAN BALKEN, Paulus, Maria [NL/NL]; C.J. Van Houtenlaan 36, NL-1381 CP Weesp (NL). ELBERS, Jules, Alex, Cornelis [NL/NL]; C.J. Van Houtenlaan 36, NL-1381 CP Weesp (NL). FRIJLINK, Henderik, Willem [NL/NL]; C.J. Van Houtenlaan 36, NL-1381 CP Weesp (NL). PHILIPS, Wienman, Emerald [NL/NL]; C.J. Van Houtenlaan 36, NL-1381 CP Weesp (NL).</p> <p>(74) Agent: BREEPOEL, Peter, Maria; Octrooibureau Zoan B.V., P.O. Box 140, NL-1380 AC Weesp (NL).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: ORAL DELAYED IMMEDIATE RELEASE FORMULATION AND METHOD OF PREPARATION THEREFOR</p>		
<p>(57) Abstract</p> <p>The invention relates to an Oral Delayed Immediate Release formulation comprising a compressed core containing one or more active substances surrounded with a coating, wherein release of active substance from the core is caused by rupture of the coating after a definite lag-time, said core comprising one or more immediate release carriers and having no substantial swelling properties upon exposure to gastrointestinal fluids. The invention further relates to formulations containing an Immediate Release formulation combined with one or more Oral Delayed Immediate Release formulations with different lag-times and to a method of preparing an Oral Delayed Immediate Release formulation. The Oral Delayed Immediate Release formulation may be used for the application of active substances whenever a certain lag-time before release is advantageous, such as in the case of anti-asthmatics, anti-emetics, cardiotonics, vasodilators, anti-vertigo and anti-ménière compounds, anti-hypertensives, sedatives, anti-depressants, anti-anxiety compounds, cortico-steroids, general anti-inflammatory compounds, anti-inflammatory compounds for gastrointestinal use, anti-ulceratives, analgetics, anti-aritmic, anti-rheumatics, anti-arthritic compounds and anti-angina compounds. The Oral Delayed Immediate Release formulation may also be used for the application of biological active compounds such as proteins, peptides, enzymes, vaccines and oligonucleotides.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ORAL DELAYED IMMEDIATE RELEASE FORMULATION AND METHOD OF PREPARATION THEREFOR

The invention relates to an oral delayed immediate release
5 formulation, to a method for preparing such a formulation and to
the combination of a delayed immediate release formulation with
an immediate release formulation.

In general, the aim of medicinal treatment is to deliver an
10 amount of an active substance to the target site within the body,
to maintain the necessary therapeutic concentration of the active
substance at the target site for some period of time and to avoid
the presence or accumulation of the active substance at the non-
target site. The concentration of the active substance at the
15 target site as a function of time may be of minor importance as
long as the therapeutic concentration is reached and not the
toxic level. In this case a simple formulation can be used for
administration of the active substance. Sometimes a relatively
constant concentration of the active substance may be desired, in
20 which case the active substance may be administered in the form
of an appropriate slow release formulation. In a number of
situations, however, it is believed that beneficial therapeutic
effects can be achieved when the active substance is administered
in such a manner that the administration is matched to variations
25 in the body in the course of the 24 hours day. This goal can
simply be achieved by administering a normal immediate release
formulation just before the point in time that a high
concentration of active substance is desired, leading to an
immediate pulsatile release of the active substance. In some
30 cases, however, e.g. when said point in time is during the night
or early in the morning, the administration can only be performed
with severe burden to the patient. In that case, but also in all
other cases where improvement of patient compliance is desirable,
the active substance can be administered via a formulation that

releases the active substance after a certain predetermined lag-time, if desired combined with an immediate release formulation.

Several approaches are known to the preparation of formulations
5 that release active substance after a certain pre-determined lag-time. EP 0210540 describes the so called Time-Controlled Explosion System, a system principally consisting of a swellable core and an outer membrane of water-insoluble material. In this system the release mechanism is based on the fact that gastro-
10 intestinal fluids penetrate through the coating and cause the swelling agent to swell. This swelling results in an "explosion" of the coating, which is followed by the release of the drug. It is claimed that the lag-time of the system can be controlled by the coating thickness. The major disadvantage of this system is
15 that it is not suitable for obtaining a pulsatile release in combination with a longer (6 to 14 hours) lag-time. The variation in lag-time is high, due to the high elasticity of the coating and the irreproducible swelling of the mentioned swelling agents. Moreover, it has been observed that the release is not pulsatile,
20 but requires several hours (1 to 3). Only when short lag-times are used, real pulsatile release occurs.

WO 93/19741 also describes a pharmaceutical formulation for time-controlled release of active substance. In this formulation the release mechanism is based on the fact that the core, containing
25 the active substance, is covered with an erodable layer or a combination of erodable layers, at least one of the erodable layers containing, as a major constituent a water-soluble cellulose derivative or a mixture of water-soluble cellulose derivatives. The disadvantage of this formulation is that it is
30 not easy to prevent leakage during the lag-time, especially when longer lag-times are desired. Furthermore it is difficult to obtain a pre-determined lag time, especially longer than 7 hours, in a reliable and reproducible way.

It is the purpose of the present invention to deliver a formulation that releases the active substance immediately after a certain pre-determined lag-time in a pulsatile manner, without substantial leakage taking place during the lag-time, Furthermore
5 the lag-time should be controlled in a reliable and reproducible way and it should be possible to produce the formulation by relatively simple and inexpensive formulation methods.

This goal can be achieved by an Oral Delayed Immediate Release
10 formulation comprising a compressed core containing one or more active substances surrounded with a coating, wherein release of active substance from the core is caused by rupture of the coating after a definite lag-time, said core comprising one or more immediate release carriers and having no substantial
15 swelling properties upon exposure to gastrointestinal fluids.

In said Oral Delayed Immediate Release formulation the release mechanism is based on the fact that the strength of the coating is gradually decreasing as a result of the impact of the aqueous
20 fluid on the coating material, finally leading to rupture of the coating as a result of the residual stress in the tablet core. Residual stress is always present in a compressed tablet core and is cause by the compression used when the core was formed. The difference with EP 0210540 is that the core of the present
25 invention does not have swelling properties. The lag-time before the release of the active substance in the present invention is caused by the intrinsic properties of the coating material, and not by the intrinsic properties of the core as in EP 0210540. Further the release of active substance is caused by rupture of
30 the coating and not by gradual dissolution or erosion of one of the main components of the coating as in WO 93/19741.

The release time of the active substance after rupture of the coating is dependent on the composition of the core. The carrier

is composed from the group of common filler-binders, e.g. cellulose, lactose, mannitol, starch and dicalcium phosphate. In order to improve the disintegration of the core after the opening of the coating, preferably a small amount of a compound having swelling properties, such as cross-linked carboxymethylcellulose, is added. The overall composition is chosen in such a way that an immediate release carrier, having no substantial swelling properties is obtained, which means that the composition of the carrier has no influence on the lag-time of the system. An immediate release carrier is defined as a carrier causing a pulsatile release.

The Oral Delayed Immediate Release formulation of the present invention preferably comprises a compressed core containing one or more active substances surrounded with a coating containing one or more polymeric materials, wherein release of active substance(s) from the core is caused by rupture of the coating after a definite lag-time, said core comprising one or more immediate release carriers and having no substantial swelling properties upon exposure to gastrointestinal fluids, and said polymeric coating materials being essentially non-soluble and/or non-erodable in gastrointestinal fluids.

Most preferably the Oral Delayed Immediate Release formulation of the present invention has a coating as defined above, also comprising 2-20 % of a water-soluble plasticizing agent and an effective amount of a brittleness-inducing agent.

In this embodiment of the present invention the release mechanism is based on the fact that the water-soluble plasticizer leaks from the coating after the tablet is placed in an aqueous fluid (like the gastro-intestinal fluids). As a result of this process the brittleness of the coating layer increases, and after a certain time the coating will crack as a result of the residual

stress in the core of the tablet. The lag time of this system can be influenced in several ways:

- When a thicker coating is used the time to dissolve and leak away of the water-soluble plasticizer will increase, as will the time at which the coating cracks.
- When more brittleness-inducing material is used, the coating will crack earlier.
- When a higher amount of plasticizer is used the lag-time will increase.

When sharp edges are present on the tablet the cracking will start at the edges resulting in a situation resembling the opening of the cover of a box (see figure 19). When the "cover of the box" has been opened, the active substance is immediately released.

In order to obtain a formulation with a reliable lag-time and a real pulsatile release the diameter is preferably more than 2 mm and most preferably more than 5 mm.

The coating material may be selected from the commercial available water-insoluble coating materials such as ethylcellulose, other water-insoluble cellulose derivatives and polymethacrylates. The preferred water-insoluble coating material is ethylcellulose (e.g. Aquacoat®).

As already described above the lag-time before release of the active substance is defined by the elasticity of the coating as a function of time which is determined by the balance between the type and amount of brittleness-inducing agent and the type and amount of plasticizing agent for a certain polymer.

The water-soluble plasticizing agent can be selected from the commercial available plasticizing agents, such as triethyl citrate, tributyl citrate, propylene glycol, polyethylene glycol, triacetin and sodium lauryl sulphate. The amount of water-soluble plasticizing agent that is needed is dependent on the type of

compound that is used. For the presently commercially available pharmaceutical plasticizers the effective amount varies between 2 and 20% of the total dry substance of the coating material. The preferred water-soluble plasticizing agent is triethyl citrate (e.g. Citroflex[®]), in a concentration of between 10% and 20% of the total dry substance of the coating material.

A brittleness-inducing agent is defined as a dose agent which decreases the elasticity of the film which forms the coating. The effective amount of brittleness-inducing agent is dependent on the type of brittleness-inducing agent that is used. The effective amount is 20 - 40 % when talc is used, 3 - 25 % in the case of aerosil and 5 - 60 % in the case of magnesium stearate, all amounts relative to the total dry substance of the coating material. The coating is prepared in such a way that the thickness of the coating remains substantially constant when the formulation is exposed to gastrointestinal fluids. Only the plasticizer leaks away from the coating.

When a coating is used containing smaller amounts of the brittleness-inducing agent, such as the coating described in US 5,158,777, no cracking of the coating will occur and the active substance will be released slowly as a result of the permeability of the coating as soon as enough water-soluble plasticizing agent has been leached out.

In order to prevent release of active substance from the formulation by means of diffusion or permeation, the coating should not comprise substantial amounts of polymeric coating materials that are soluble and/or erodable in gastrointestinal fluids. These type of formulations are disclosed in US 4,798,724, describing a formulation containing the water-soluble coating material Klucel[®], leading to decomposition of the coating when the formulation is exposed to gastrointestinal fluid, in EP 0431877 describing a coating which is soluble in intestinal juice from pH 5.5 upwards, leading to a pH dependent release of the

active substance instead of a time-dependent release, and in EP 0655 240 describing a formulation wherein the coating is eroded, leading to an increasing permeability and consequently diffusion of the active substance through the coating.

5 A permeable coating may also be obtained when quaternary ammonium groups are present in the polymeric coating material of a specific composition, leading to sustained release of the active compound and not to a pulsatile release after a certain lag-time. Such a sustained release formulation is described in EP 0502642.

10

The formulation according to the present invention can be used both for human and veterinary applications.

Typical indications wherein an Oral Delayed Immediate Release Formulation will be beneficial are indications wherein a peak
15 level of active substance is desirable in the early morning, such as in the case of antiasthmatics (e.g. bronchodilators), antiemetics, cardiotonics, vasodilators, anti-vertigo and anti-ménière drugs (e.g. betahistine) and anti-hypertensives. However, also for other indications the formulation can be very useful to
20 improve patient compliance, e.g. for sedatives as diazepam for antidepressants as fluvoxamine and flesinoxan, for anti-anxiety compounds as alprazolam and flesinoxan and for other CNS compounds. Other interesting groups of drugs may be: anti-inflammatory drugs for gastro-intestinal use (for treatment of
25 disorders like Crohn's disease or colitis ulcerosa or irritable bowel (e.g. mebeverine)), anti-ulceratives, anti-asthmatics, corticosteroids such as prednisone, other anti-inflammatory drugs, analgetics, anti-rheumatics, anti-arthritic drugs and anti-angina drugs.

30

Another class of active compounds that can be formulated in an Oral Delayed Immediate Release formulation are bio-active proteins, peptides, enzymes (e.g. pancreatin), vaccines (e.g. influenza vaccine) and oligonucleotides. Very often these type of

compounds are not resistant to the very acidic environment in the stomach. Furthermore it may be desirable to administer said type of compounds in a pulsatile way as recently described by Cardomone et al (J. Contr. Rel. 1997, 47, 205-219) for a delivery
5 system for immunisation against tetanus toxoid.

A further improvement of patient compliance can be reached when formulations with different release lag-times are combined in a single dosage form. Therefore the present invention also relates
10 to an Oral Delayed Immediate Release formulation as defined above, characterized in that said Oral Delayed Immediate Release formulation has a certain release lag-time and is combined in one capsule with an Oral Immediate Release formulation and/or one or
15 more Oral Delayed Immediate Release formulations with a different release lag-time. The capsule may consist of common material, such as gelatin or starch derivatives. In an alternative single dosage form the formulation of the invention is surrounded with an Oral Immediate Release Formulation. Therefore the present
20 invention also relates to an Oral Delayed Immediate Release formulation as defined above, characterized in that said Oral Delayed Immediate Release formulation is surrounded with an Oral Immediate Release formulation.

The present invention also relates to the use of a combination of
25 one or more active substances, core-forming substances and coating-forming substances, for the manufacture of an Oral Delayed Immediate Release formulation comprising a compressed core surrounded with a coating, said core comprising one or more active substances and one or more immediate release carriers,
30 wherein release of active substance is caused by rupture of the outer membrane after a definite lag-time, characterized in that said Oral Delayed Immediate Release formulation has the composition as described above.

The present invention also relates to a method of preparing an Oral Delayed Immediate Release formulation as described above, characterized in that (1) a core is compressed of a mixture comprising one or more active substances and one or more
5 immediate release carriers, (2) the compressed core is coated with a mixture of coating materials, said core and said coating having the properties and/or composition as described above.

As described above the Oral Delayed Immediate Release formulation
10 can be combined with an Oral Immediate Release formulation or an Oral Delayed Immediate Release formulation with a different lag-time in one single embodiment. Therefore the present invention also relates method of preparing an Oral Delayed Immediate
15 Release formulation as described above, characterized in that (1) a core is compressed of a mixture comprising one or more active substances and one or more immediate release carriers, (2) the compressed core is coated with one or more coating materials and that (3) the first Oral Immediate Release formulation is (i)
20 combined in a capsule with an Oral Immediate Release formulation and/or one or more Oral Delayed Immediate Release formulations with a different release lag-time, or (ii) surrounded with an Oral Immediate Release formulation, a mixture of coating materials, said core and said coating having the properties and/or composition as described above.

25 It is an advantage of the present invention that the formulation can be prepared using commercial available formulation materials and relatively simple and inexpensive formulation methods.

30 The invention will now be described in greater detail with reference to the following specific Examples.

Examples

EXAMPLE 1

To investigate the influence of the amount of cross-linked carboxymethylcellulose in the core tablets, several coated
5 tablets, with different amount of cross-linked carboxymethylcellulose, are produced. The production of the core tablets is performed in the following way:

1. micro-crystalline cellulose is granulated, by adding
10 the aqueous solution of betahistine.2HCl, in a high shear mixer.
2. the yield of 1. is dried and screened.
3. the yield of 2. is mixed with the talc and optionally with the cross-linked carboxymethylcellulose.
4. the yield of 3. is compressed to tablets of \varnothing 5.0 mm
15 and a weight of 100 mg each.

The coating of the core tablets is performed in the following way:

5. the coating suspension is prepared by mixing
20 ethylcellulose, plasticizing agent and brittleness-inducing agent in the desired ratio with water, until a suspension with a dry substance content of 20% is obtained.
6. in a coating pan or fluid bed, the yield of 4 (the
25 core tablets), is coated with the yield of 5, until the required weight of the tablets is obtained.

After coating, tablets, having the following composition, in mg per tablet, are obtained:

Exipients	Exp. a	Exp. b	Exp. c	Exp .d	Exp. e	Exp. f
<u>Core:</u>						
betahistine.2HCl	27.8	27.8	27.8	27.8	27.8	27.8
micro-crystalline cellulose	69.2	67.2	65.2	65.2	64.2	62.2
talc	3.0	3.0	3.0	3.0	3.0	3.0
cross-linked carboxymethylcellulose	0.0	2.0	4.0	4.0	5.0	7.0
<u>Coating:</u>						
ethylcellulose	14.3	14.1	14.5	14.1	14.3	14.5
Citroflex ^R 2	3.0	3.0	3.1	3.0	3.0	3.1
talc	8.6	8.5	8.7	8.5	8.6	8.7
	-----	-----	-----	-----	-----	-----
Total	125.9	125.6	126.3	125.6	125.9	126.3

In-vitro dissolution studies with the USP apparatus II, with half change release medium and a rotation speed of the paddle of 50 rpm are performed.

The results are summarized in the next table:

Core tablets		Coating (%)	Mean start time of the release (n = 6)
Experiment	Amount cross-linked carboxymethylcellulose (%)		
a	0	20.5	7.2 hours
b	2	20.4	6.0 hours
c	4	20.8	7.0 hours
d	4	20.4	7.5 hours
e	5	20.6	7.6 hours
f	7	20.8	7.5 hours

10 From these experiments it can be concluded that the addition of a super disintegrating agent has no influence on the lag-time.

EXAMPLE 2

Core tablets with the composition of experiment f of example 1 are prepared as described in example 1, followed by coating with a thicker coating.

Composition, in mg per tablet:

Exipients	Example 2
<u>Core:</u>	
betahistine.2HCl	27.8
micro-crystalline cellulose	62.2
talc	3.0
cross-linked carboxymethylcellulose	7.0
<u>Coating:</u>	
ethylcellulose	19.6
Citroflex ^R 2	4.1
talc	3.9

Total	127.6

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with water as release medium and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 1):

Example 2	Release (%) after sampling time (in hours):									
	7.0	8.0	9.0	10.0	11.0	12.0	13.0	14.0	15.0	16.0
channel 1	0	0	0	0	0	0	100	100	100	
channel 2	0	0	0	0	0	0	0	56	100	
channel 3	0	0	0	0	0	0	0	0	0	0
channel 4	0	0	0	0	0	100	100	100	100	
channel 5	0	0	0	0	28	100	100	100	100	
channel 6	0	0	0	0	100	100	100	100	100	

From this experiment it can be concluded that a thicker coating combined with a lower amount of brittleness-inducing agent leads to a longer lag-time.

5 **EXAMPLE 3**

Core tablets with the composition of experiment f of example 1 are prepared as described in example 1, followed by coating with a suspension containing a lower amount of talc.

10 Composition, in mg per tablet:

Exipients	Example 3
<u>Core:</u>	
betahistine.2HCl	27.8
micro-crystalline cellulose	62.2
talc	3.0
cross-linked carboxymethylcellulose	7.0
<u>Coating:</u>	
ethylcellulose	17.6
Citroflex ^R 2	3.7
talc	5.3

Total	126.6

15 In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with water as release medium and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 2):

Example 3	Release (%) after sampling time (in hours):									
	7.0	8.0	9.0	10.0	11.0	12.0	13.0	14.0	15.0	16.0
channel 1	0	0	0	84	100					
channel 2	0	0	0	9	100					
channel 3	0	0	0	0	100					
channel 4	0	0	0	100	100					
channel 5	0	0	0	0	100					
channel 6	0	0	24	100	100					

From this experiment it can be concluded that a lower amount of brittleness-inducing agent leads to a longer lag-time.

5 **EXAMPLE 4**

Core tablets with the composition of experiment f of example 1 are prepared as described in example 1, followed by coating with a suspension containing a higher amount of talc.

10 Composition, in mg per tablet:

Exipients	Example 4
<u>Core:</u>	
betahistine.2HCl	27.8
micro-crystalline cellulose	62.2
talc	3.0
cross-linked carboxymethylcellulose	7.0
<u>Coating:</u>	
ethylcellulose	16.2
Citroflex ^R 2	3.4
talc	6.5

Total	126.1

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with water as release medium and a rotation speed

of the paddle of 50 rpm gives the following results (also depicted in figure 3):

Example 4	Release (%) after sampling time (in hours):									
	7.0	8.0	9.0	10.0	11.0	12.0	13.0	14.0	15.0	16.0
channel 1	0	0	59	100	100					
channel 2	0	0	0	71	100					
channel 3	0	0	12	100	100					
channel 4	0	97	100	100	100					
channel 5	0	0	0	58	100					
channel 6	0	78	100	100	100					

From this experiment and the experiments described in examples 1 and 3 it can be concluded that the lag-time before release can be influenced by the amount of brittleness-inducing agent.

EXAMPLE 5

Core tablets with the composition of experiment f of example 1 are prepared as described in example 1, followed by coating with a suspension containing a higher amount of talc.

Composition, in mg per tablet:

Exipients	Example 5
<u>Core:</u>	
betahistine.2HCl	27.8
micro-crystalline cellulose	62.2
talc	3.0
cross-linked carboxymethylcellulose	7.0
<u>Coating:</u>	
ethylcellulose	15.1
Citroflex ^R 2	3.2
talc	7.6

Total	125.9

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with water as release medium and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 4):

5

Example 5	Release (%) after sampling time (in hours):											
	5.0	6.0	7.0	8.0	9.0	10.0	11.0	12.0	13.0	14.0	15.0	16.0
channel 1	0	0	100	100	100							
channel 2	0	0	87	100	100							
channel 3	0	40	100	100	100							
channel 4	0	0	10	100	100							
channel 5	0	0	0	100	100							
channel 6	0	0	100	100	100							

From this experiment and the experiments described in examples 1, 3 and 4 it can be concluded that the lag-time before release can be influenced by the amount of brittleness-inducing agent.

10

EXAMPLE 6

Core tablets with the composition of experiment f of example 1 are prepared as described in example 1, followed by coating with a suspension containing a higher amount of talc.

15

Composition, in mg per tablet:

Exipients	Example 6
<u>Core:</u>	
betahistine.2HCl	27.8
micro-crystalline cellulose	62.2
talc	3.0
cross-linked carboxymethylcellulose	7.0
<u>Coating:</u>	
ethylcellulose	15.1
Citroflex ^R 2	3.2
talc	7.6

Total	125.9

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 5):

Example 6	Release (%) after sampling time (in hours):									
	6.0	7.0	8.0	9.0	10.0	11.0	12.0	14.0	15.0	16.0
channel 1	0	0	92	100	100					
channel 2	0	0	82	100	100					
channel 3	0	0	32	100	100					
channel 4	0	0	99	100	100					
channel 5	0	0	100	100	100					
channel 6	0	0	25	100	100					

From this experiment and the experiment described in example 5, it can be concluded that the formulation according to the present can be prepared in a reproducible way.

EXAMPLE 7

Core tablets with the composition of experiment f of example 1 are prepared as described in example 1, followed by coating with a suspension containing magnesium stearate as brittleness-inducing agent instead of talc.

Composition, in mg per tablet:

Exipients	Example 7
<u>Core:</u>	
betahistine.2HCl	27.8
micro-crystalline cellulose	62.2
talc	3.0
cross-linked carboxymethylcellulose	7.0
<u>Coating:</u>	
ethylcellulose	13.1
Citroflex ^R 2	2.8
Mg stearate	3.9

Total	119.8

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 6):

Example 7	Release (%) after sampling time (in hours):									
	1.0	1.5	2.0	2.5	3.0	3.5	4.0	4.5	5.0	5.5
channel 1	0	0	0	0	100	100	100			
channel 2	0	0	0	0	0	0	100			
channel 3	0	0	0	0	99	100	100			
channel 4	0	0	0	0	33	100	100			
channel 5	0	0	0	0	100	100	100			
channel 6	0	0	16	30	94	100	100			

From this experiment it can be concluded that the type of brittleness-inducing agent in the coating has a large influence on the lag-time before release of the drug substance.

5 **EXAMPLE 8**

Core tablets with the composition of experiment f of example 1 are prepared as described in example 1, followed by coating with a suspension containing triacetyl glycerine as plasticizing agent
10 instead of Citroflex®.

Composition, in mg per tablet:

Exipients	Example 8
<u>Core:</u>	
betahistine.2HCl	27.8
micro-crystalline cellulose	62.2
talc	3.0
cross-linked carboxymethylcellulose	7.0
<u>Coating:</u>	
ethylcellulose	14.1
triacetyl glycerine	3.0
talc	8.5

Total	125.6

In-vitro dissolution study of 6 coated tablets with the USP
15 apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 7):

Example 8	Release (%) after sampling time (in hours):									
	1.0	1.5	2.0	2.5	3.0	3.5	4.0	4.5	5.0	5.5
channel 1	0	0	100	100						
channel 2	0	0	100	100						
channel 3	0	0	100	100						
channel 4	0	0	100	100						
channel 5	0	0	100	100						
channel 6	0	0	98	100						

From this experiment and the experiments described in example 1, it can be concluded that type of plasticizing agent in the coating has a large influence on the lag-time before release of the drug substance.

EXAMPLE 9

Core tablets with the composition of experiment a of example 1 are prepared as described in example 1, followed by coating.

Composition, in mg per tablet:

Exipients	Example 9
Core:	
betahistine.2HCl	28.8
micro-crystalline cellulose	68.3
talc	2.9
cross-linked carboxymethylcellulose	0
Coating:	
ethylcellulose	14.1
Citroflex ^R 2	3.0
talc	8.5
Total	----- 125.6

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 8):

5

Example 9	Release (%) after sampling time (in hours):												
	7.0	7.5	8.0	8.5	9.0	9.5	10.0	10.5	11.0	11.5	12.0	12.5	13.0
channel 1	0	0	0	0	16	57	80	92	99	100			
channel 2	0	0	0	0	19	57	79	90	97	100			
channel 3	0	64	91	100	100	100	100	100	100	100			
channel 4	0	0	0	35	67	83	93	98	100	100			
channel 5	0	0	0	0	40	70	87	94	100	100			
channel 6	0	0	0	30	65	84	94	99	100	100			

From this experiment it can be concluded that the absence of a small amount of a compound having swelling properties leads to a more gradual release of the drug substance after the lag-time.

10

EXAMPLE 10

Core tablets with about the composition of experiment d of example 1 are prepared as described in example 1, followed by coating as described in example 1.

15

Composition, in mg per tablet:

Exipients	Example 10
<u>Core:</u>	
betahistine.2HCl	27.8
micro-crystalline cellulose	65.7
talc	2.8
cross-linked carboxymethylcellulose	3.7
<u>Coating:</u>	
ethylcellulose	14.2
Citroflex ^R 2	3.0
talc	8.6

Total	125.9

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 9):

Example 10	Release (%) after sampling time (in hours):												
	7.0	7.5	8.0	8.5	9.0	9.5	10.0	10.5	11.0	11.5	12.0	12.5	13.0
channel 1	0	0	0	0	69	100	100	100					
channel 2	0	0	0	69	100	100	100	100					
channel 3	0	0	0	0	9	82	100	100					
channel 4	0	0	0	0	0	0	72	100					
channel 5	0	27	100	100	100	100	100	100					
channel 6	0	0	0	0	33	98	100	100					

EXAMPLE 11

Core tablets with about the composition of experiment f of example 1 are prepared as described in example 1, followed by coating as described in example 1.

Composition, in mg per tablet:

Exipients	Example 11
Core:	
betahistine.2HCl	27.8
micro-crystalline cellulose	62.2
talc	3.0
cross-linked carboxymethylcellulose	7.0
Coating:	
ethylcellulose	14.5
Citroflex ^R 2	3.0
talc	8.7

Total	126.2

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 10):

Example 11	Release (%) after sampling time (in hours):												
	7.0	7.5	8.0	8.5	9.0	9.5	10.0	10.5	11.0	11.5	12.0	12.5	13.0
channel 1			0	29	98	100	100						
channel 2			0	0	95	100	100						
channel 3			0	0	83	100	100						
channel 4			0	0	0	80	100						
channel 5			0	0	0	100	100						
channel 6			0	70	100	100	100						

EXAMPLE 12

Core tablets with the composition of experiment f of example 1 are prepared as described in example 1, followed by coating with a higher amount of coating with the same composition as in experiment f of example 1.

Composition, in mg per tablet:

Exipients	Example 12
<u>Core:</u>	
betahistine.2HCl	27.8
micro-crystalline cellulose	62.2
talc	3.0
cross-linked carboxymethylcellulose	7.0
<u>Coating:</u>	
ethylcellulose	21.2
Citroflex ^R 2	4.5
talc	12.7

Total	138.4

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 11):

Example 12	Release (%) after sampling time (in hours):											
	9.0	9.5	10.0	10.5	11.0	11.5	12.0	12.5	13.0	13.5	14.0	14.5
channel 1							0	0	0	9	78	100
channel 2							0	14	100	100	100	100
channel 3							0	56	100	100	100	100
channel 4							0	0	3	74	100	100
channel 5							0	0	29	100	100	100
channel 6							0	0	48	82	100	100

From this experiment it can be concluded that a thicker coating of the same relative composition as in the experiments described in example 1 leads to a longer lag-time.

EXAMPLE 13

Core tablets with the composition of experiment c of example 1 are prepared as described in example 1, followed by coating a lower amount of coating material as described in experiment c of example 1, on a scale of 100,000 (10 kg) coated tablets.

Composition, in mg per tablet:

Exipients	Example 13
Core:	
betahistine.2HCl	27.8
micro-crystalline cellulose	65.2
talc	3.0
cross-linked carboxymethylcellulose	4.0
Coating:	
ethylcellulose	9.0
Citroflex ^R 2	1.9
talc	6.8

Total	117.7

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 12):

Example 13	Release (%) after sampling time (in hours):											
	7.0	7.5	8.0	8.5	9.0	9.5	10.0	10.5	11.0	11.5	12.0	12.5
channel 1	0	0	83	100	100	100	100	100	100			
channel 2	0	0	0	0	91	100	100	100	100			
channel 3	0	0	0	79	100	100	100	100	100			
channel 4	90	100	100	100	100	100	100	100	100			
channel 5	0	0	0	0	40	70	87	94	100			
channel 6	0	0	51	100	100	100	100	100	100			

From this experiment it can be concluded that the invented formulation can be prepared on a scale of 100,000 (10 kg) coated tablets.

EXAMPLE 14

Core tablets with the composition of experiment c of example 1 are prepared as described in example 1, followed by coating a lower amount of coating material as described in experiment c of example 1, on a scale of 500,000 (50 kg) coated tablets.

Composition, in mg per tablet:

Exipients	Example 14
<u>Core:</u>	
betahistine.2HCl	27.8
micro-crystalline cellulose	65.2
talc	3.0
cross-linked carboxymethylcellulose	4.0
<u>Coating:</u>	
ethylcellulose	10.3
Citroflex ^R 2	2.2
talc	7.7

Total	120.2

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 13):

Example 14	Release (%) after sampling time (in hours):										
	7.0	7.5	8.0	8.5	9.0	9.5	10.0	10.5	11.0	11.5	12.0
channel 1	0	77	100	100	100	100					
channel 2	0	0	0	61	100	100					
channel 3	0	0	39	100	100	100					
channel 4	0	0	0	81	100	100					
channel 5	0	0	0	0	0	100					
channel 6	0	21	100	100	100	100					

From this experiment it can be concluded that the invented formulation can be prepared on a scale of 500,000 (50 kg) coated tablets.

5 **EXAMPLE 15**

In an exploratory, three-way cross-over bioavailability study the rate and the extent of absorption of betahistine after oral administration of conventional and experimental oral delayed
10 immediate release (TSR) betahistine formulations was investigated. In addition, the safety and tolerability of these betahistine formulations was evaluated. A TSR formulation consisted of a gelatin capsule containing an immediate release
15 formulation and a delayed immediate release formulation as described in example 11 (TSR(0/8)) or example 12 (TSR(0/12)).

Eight healthy male subjects between 18 - 45 years and with a weight between 60 - 95 kg were included. The eligibility screening consisted of a clinical laboratory examination, medical history, vital signs, ECG and tests on drugs of abuse.

20 There were four treatments relevant for this application: I: conventional 24 mg formulation at t= 0 h and t= 8 h; II: conventional 24 mg formulation at t= 0 h and t= 12 h.; III: TSR (0/8) C 48 mg formulation at t=0 and IV: TSR (0/12) D 48 mg
25 formulation at t=0. Four subjects received treatments I and III and four subjects received treatments II and IV.

The washout period between treatments (morning doses) was 48 hours. The total study duration was 8 days. Urine sampling was done before each dose and in 2 hours fractions up to 18 h, 18-24 h, 24-36 h and 36-48 h after each dose. Safety assessments were
30 done once on screening and after study termination.

The urine samples were analyzed for the concentration of 2-PAA, the major metabolite of betahistine. The cumulative urinary excretion of 2-PAA in the urine was calculated for each treatment. The results showed that formulation C (treatment III)

released one dose just after intake and the second dose 12 hours after the first dose. Figure 14 shows that the urinary excretion profile after treatment III is comparable with that after treatment II, in which conventional tablets were taken twice daily. The safety and tolerability data showed that all treatments were well tolerated. All subjects completed the trial. No clinical significant abnormalities in safety parameters occurred.

EXAMPLE 16

To investigate the applicability of the present invention in the formulation of prednisone, core tablets containing prednisone are prepared by the procedure described in example 1, followed by coating according to the procedure described in example 1. Composition, in mg per tablet:

Excipients	Example 16
Core:	
prednisone	4.2
micro-crystalline cellulose	132.4
talc	4.1
cross-linked carboxymethylcellulose	5.4
Coating:	
ethylcellulose	23.4
Citroflex ^R 2	4.9
talc	14.1

Total	188.5

In-vitro dissolution study of coated tablets with the USP apparatus II, with water as release medium and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 15):

Prednison Example 16	Release (%) after sampling time (in hours):												
	5	5.5	6	6.5	7	7.5	8	8.5	9	9.5	10	10.5	11
Channel 1	0	0	0	0	0	0	0	0	0	0	0	0	0
Channel 2	0	0	0	0	87	98	100	100	100	100	100	100	100
Channel 3	0	0	0	0	0	99	100	100	100	100	100	100	100
Channel 4	0	0	0	0	0	100	100	100	100	100	100	100	100
Channel 5	0	0	0	0	49	100	100	100	100	100	100	100	100
Channel 6	0	0	0	50	97	100	100	100	100	100	100	100	100

From the experiments it can be concluded that it is possible to prepare an Oral Immediate Release formulation of prednisone, according to the present invention.

EXAMPLE 17

To investigate the applicability of the present invention in the formulation of flesinoxan, core tablets containing flesinoxan are prepared by the procedure described in example 1, followed by coating according to the procedure described in example 1.

Composition, in mg per tablet:

Excipients	Example 17
<u>Core:</u>	
flesinoxan	19.9
micro-crystalline cellulose	70.4
talc	4.5
cross-linked carboxymethylcellulose	3.5
<u>Coating:</u>	
ethylcellulose	20.2
Citroflex ^R 2	4.2
talc	12.1

Total	134.8

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with water as release medium and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 16):

Flesinoxan Example 17	Release (%) after sampling time (in hours):												
	1	2	3	4	5	6	7	8	9	10	11	12	13
Channel 1	0	0	0	0	0	0	56	89	94	96	97	99	100
Channel 2	0	0	0	0	0	0	0	75	93	95	93	97	97
Channel 3	0	0	0	0	0	0	0	94	99	97	97	98	98
Channel 4	0	0	0	0	0	0	0	82	105	107	107	108	108
Channel 5	0	0	0	0	0	0	0	90	96	95	97	98	98
Channel 6	0	0	0	0	0	0	0	92	98	98	100	102	102

5

From the experiments it can be concluded that it is possible to prepare an Oral Immediate Release formulation of flesinoxan, according to the present invention.

10 **EXAMPLE 18**

To investigate the applicability of the present invention in the formulation of diazepam, core tablets containing diazepam are prepared by the procedure described in example 1, followed by
15 coating according to the procedure described in example 1.

Composition, in mg per tablet:

Excipients	Example 18
<u>Core:</u>	
diazepam	3.6
micro-crystalline cellulose	103.0
talc	3.5
cross-linked carboxymethylcellulose	4.7
<u>Coating:</u>	
ethylcellulose	14.8
Citroflex ^R 2	3.1
talc	8.9

Total	141.6

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 17):

Diazepam Example 18	Release (%) after sampling time (in hours):												
	5	5.5	6	6.5	7	7.5	8	8.5	9	9.5	10	10.5	11
Channel 1	0	0	0	0	61	85	89	90	90	90	90	90	90
Channel 2	0	0	0	0	53	78	83	84	84	84	84	84	84
Channel 3	0	0	0	0	0	0	81	99	100	100	100	100	100
Channel 4	0	0	0	0	0	0	64	78	88	90	91	91	91
Channel 5	0	0	0	0	0	0	0	0	42	86	87	87	87
Channel 6	0	0	0	0	0	0	0	73	91	96	97	97	97

From the experiments it can be concluded that it is possible to prepare an Oral Immediate Release formulation of diazepam, according to the present invention.

EXAMPLE 19

To investigate the applicability of the present invention in the formulation of mebeverine, core tablets containing mebeverine are prepared by the procedure described in example 1, followed by coating according to the procedure described in example 1.

Composition, in mg per tablet:

Excipients	Example 19
<u>Core:</u>	
mebeverine	38.6
micro-crystalline cellulose	56.0
talc	4.7
cross-linked carboxymethylcellulose	4.8
<u>Coating:</u>	
ethylcellulose	12.6
Citroflex ^R 2	2.6
talc	9.4

Total	128.7

In-vitro dissolution study of 6 coated tablets with the USP apparatus II, with half change release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results (also depicted in figure 18):

Mebeverine Example 19	Release (%) after sampling time (in hours):									
	7.0	8.0	9.0	10.0	11.0	12.0	13.0	14.0	15.0	16.0
Channel 1	0	0	0	0	0	33	63	69	74	78
Channel 2	0	0	0	0	0	0	6	70	78	82
Channel 3	0	0	0	0	0	0	40	69	77	81
Channel 4	0	0	0	0	0	0	0	59	91	98
Channel 5	0	0	0	0	0	0	57	63	68	73
Channel 6	0	0	0	0	0	0	59	70	74	78

From the experiments it can be concluded that it is possible to prepare an Oral Immediate Release formulation of mebeverine, according to the present invention.

5 **EXAMPLE 20**

To investigate the applicability of the present invention in the formulation of a vaccine, core tablets containing influenza vaccine are prepared by the procedure described in example 1,
10 followed by coating according to the procedure described in example 1.

Composition, in mg per tablet:

Excipients	Example 20
<u>Core:</u>	
Influenza vaccine (bioactive protein)	0.325
micro-crystalline cellulose	105.1
talc	0.6
cross-linked carboxymethylcellulose	6.7
<u>Coating:</u>	
ethylcellulose	9.6
Citroflex ^R 2	2.3
talc	7.2

Total	131.8

In absence of an applicable method for the measurement of the
15 release of the bioactive protein as a function of time, the time of delay (lag time) of the release of the active compound by means of the visual appearance of the coated tablet is determined (opening of the "cover of the box"). The time of delay of 6 tablets with the USP apparatus II, with half change
20 release medium (pH=1.2 followed by pH=6.8) and a rotation speed of the paddle of 50 rpm gives the following results:

	Tablet 1	Tablet 2	Tablet 3	Tablet 4	Tablet 5	Tablet 6
time of delay (in minutes)	231	201	228	223	223	218

After the release of the content of the core, the content of bioactive protein is measured. About 25% (about 75 μ g per 5 tablet) of the bioactive protein is available.

From the experiments it can be concluded that it is possible to prepare an Oral Immediate Release formulation of a bioactive protein according to the present invention.

Claims

1. An Oral Delayed Immediate Release formulation comprising a
5 compressed core containing one or more active substances
surrounded with a coating, wherein release of active substance
from the core is caused by rupture of the coating after a
definite lag-time, said core comprising one or more immediate
10 release carriers and having no substantial swelling properties
upon exposure to gastrointestinal fluids.

2. An Oral Delayed Immediate Release formulation comprising a
compressed core containing one or more active substances
surrounded with a coating containing one or more polymeric
15 coating materials, wherein release of active substance(s) from
the core is caused by rupture of the coating after a definite
lag-time, said core comprising one or more immediate release
carriers and having no substantial swelling properties upon
exposure to gastrointestinal fluids, and said polymeric coating
20 materials being essentially non-soluble and/or non-erodable in
gastrointestinal fluids.

3. An Oral Delayed Immediate Release formulation according to
claim 2, characterized in that said coating comprises 2-20 % of a
25 water-soluble plasticizing agent and an effective amount of a
brittleness-inducing agent

4. An Oral Delayed Immediate Release formulation according to
claim 3, characterized in that said water-soluble plasticizing
30 agent is selected from the group consisting of triethyl citrate,
tributyl citrate, propylene glycol, polyethylene glycol,
triacetin and sodium lauryl sulphate.

5. An Oral Delayed Immediate Release formulation according to claim 3 and 4, characterized in that said water-soluble plasticizing agent is triethylcitrate.
- 5 6. An Oral Delayed Immediate Release formulation according to claim 3-5, characterized in that said brittleness-inducing agent is added in an amount between 3 and 60%.
7. An Oral Delayed Immediate Release formulation according to
10 claim 6, characterized in that said brittleness-inducing agent is selected from the group consisting of 20 - 40 % of talc, 3 - 25 % of aerosil and 5 - 60 % of magnesium stearate.
8. An Oral Delayed Immediate Release formulation according to
15 claim 7, characterized in that said brittleness-inducing agent is 20 - 40 % of talc.
9. An Oral Delayed Immediate Release formulation according to
20 claim 2-8, characterized in that said polymeric coating material essentially consists of ethylcellulose.
10. An Oral Delayed Immediate Release formulation according to
claim 1-9, characterized in that said formulation has a diameter of more than 2 mm, preferably more than 5 mm.
- 25
11. An Oral Delayed Immediate Release formulation according to
claim 1-10, characterized in that said active substance is a pharmaceutical compound selected from the group consisting of
anti-asthmatics, anti-emetics, cardiotonics, vasodilators, anti-
30 vertigo and anti-ménière compounds, anti-hypertensives, sedatives, antidepressants, anti-anxiety compounds, corticosteroids, general anti-inflammatory compounds, anti-inflammatory compounds for gastrointestinal use, anti-ulceratives, analgetics,

anti-aritmics, anti-rheumatics, anti-arthritic compounds and anti-angina compounds.

12. An Oral Delayed Immediate Release formulation according to
5 claim 1-10, characterized in that said active substance is a biological active compound selected from the group consisting of proteins, peptides, enzymes, vaccines and oligonucleotides.

13. An Oral Delayed Immediate Release formulation according to
10 claim 12, characterized in that said biologically active substance is a vaccine.

14. An Oral Delayed Immediate Release formulation according to
15 claim 13, characterized in that said vaccine is influenza vaccine.

15. An Oral Delayed Immediate Release formulation according to
claim 1-14, characterized in that said Oral Delayed Immediate
Release formulation has a certain release lag-time and is
20 combined in one capsule with an Oral Immediate Release formulation and/or one or more Oral Delayed Immediate Release formulations with a different release lag-time.

16. An Oral Delayed Immediate Release formulation according to
25 claim 1-14, characterized in that said Oral Delayed Immediate Release formulation is surrounded with an Oral Immediate Release formulation.

17. A method of preparing an Oral Delayed Immediate Release
30 formulation according to claim 1-14, characterized in that (1) a core is compressed of a mixture comprising one or more active substances and one or more immediate release carriers, (2) the compressed core is coated with a mixture of coating materials,

said core and said coating having the properties and/or composition as claimed in claim 1-14.

18. A method of preparing an Oral Delayed Immediate Release
5 formulation according to claim 15-16, characterized in that (1) a
core is compressed of a mixture comprising one or more active
substances and one or more immediate release carriers, (2) the
compressed core is coated with one or more coating materials and
that (3) the first Oral Immediate Release formulation is (i)
10 combined in a capsule with an Oral Immediate Release formulation
and/or one or more Oral Delayed Immediate Release formulations
with a different release lag-time, or (ii) surrounded with an
Oral Immediate Release formulation, a mixture of coating
materials, said core and said coating having the properties
15 and/or composition as claimed in claim 15-16.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17





Figure 18

Figure 19



INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 97/05234

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/28 A61K9/48 A61K31/44 A61K39/145 A61K38/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	US 4 897 270 A (DEUTSCH DAVID S ET AL) 30 January 1990 * col.2, 1.5-11; col.3, 1.15-67; Ex.1-7; claims 1-19 *	1,2, 9-11, 15-18
X	US 4 798 724 A (S.C. KHANNA) 17 January 1989 cited in the application * col.2, 1.21-22; Ex.1 and 2; claims 1-8 *	1,6-8, 10,16-18
X	EP 0 431 877 A (SMITHKLINE BEECHAM LAB PHARM) 12 June 1991 cited in the application * p.4, 1.44-57; p.5, 1.54-p.6, 1.16, 1.Ex.1-5, 10-15; claims 1-23 *	1-10, 15-18
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

^o Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

5 February 1998

Date of mailing of the international search report

20. 02. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Uiber, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/05234

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EP 0 655 240 A (EUROCELTIQUE SA) 31 May 1995 cited in the application * p.3, l.51-57; p.5, l.20-31; p.7, l.6-20, l.45-51; p.8, l.48-52; p.9, l.56-p.10, l.5; p.10, l.55-p.11, l.10; claims 1-13 *</p>	<p>1-5,9, 11,12, 15-18</p>
Y	<p>see the whole document</p>	<p>6-8,10, 11,15</p>
Y	<p style="text-align: center;">---</p> <p>US 5 229 131 A (AMIDON ET AL) 20 July 1993 * claims 1-12; col.3, l.13-46; col.5, l.10-14; col.8, l.39, l.49-50; col.9, l.23-35; col.25, l.20-44;</p>	<p>1-18</p>
Y	<p style="text-align: center;">---</p> <p>EP 0 396 425 A (KV PHARMACEUTICAL COMPANY) 7 November 1990 see claims 1-14,32-36</p>	<p>1-18</p>
A	<p style="text-align: center;">---</p> <p>EP 0 502 642 A (RECKITT & COLMANN PROD LTD) 9 September 1992 cited in the application * p.3, l.7; Ex.1-7; claims 1-11 *</p>	<p>1-11</p>
A	<p style="text-align: center;">---</p> <p>WO 93 19741 A (BENZON PHARMA AS ;BERTELSEN POUL (DK); HANSEN NILS GJERLOV (DK); J) 14 October 1993 cited in the application see the whole document</p>	<p>1-18</p>
A	<p style="text-align: center;">---</p> <p>EP 0 420 459 A (WARNER LAMBERT CO) 3 April 1991 see the whole document</p> <p style="text-align: center;">-----</p>	<p>12-14</p>

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/05234

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4897270 A	30-01-90	AT 393081 B	12-08-91
		AU 594082 B	01-03-90
		AU 6323286 A	02-04-87
		BE 905518 A	30-03-87
		CA 1282331 A	02-04-91
		CH 672736 A	29-12-89
		CY 1563 A	17-05-91
		DE 3633292 A	09-04-87
		DK 462486 A	31-03-87
		EP 0223365 A	27-05-87
		FR 2591597 A	19-06-87
		GB 2181052 A,B	15-04-87
		HK 84990 A	25-10-90
		IE 59089 B	12-01-94
		JP 2661662 B	08-10-97
		JP 62123118 A	04-06-87
		KR 9400233 B	12-01-94
		LU 86613 A	05-04-88
		NL 8602466 A	16-04-87
		NO 173636 C	12-01-94
		PH 25702 A	18-09-91
		SE 8604114 A	31-03-87

US 4798724 A	17-01-89	CH 666405 A	29-07-88
		AT 396330 B	25-08-93
		AU 593259 B	08-02-90
		AU 5894486 A	08-01-87
		BE 904976 A	23-12-86
		CA 1277238 A	04-12-90
		DE 3620631 A	02-01-87
		DK 294586 A	25-12-86
		FI 88675 C	28-06-93
		FR 2583638 A	26-12-86
		GB 2176704 A,B	07-01-87
		IE 58459 B	22-09-93
		JP 62000421 A	06-01-87
		JP 1995120 C	22-11-95
		JP 7033330 B	12-04-95
		JP 62000420 A	06-01-87
		LU 86477 A	13-01-87

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/05234

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4798724 A		NL 8601627 A SE 463850 B SE 8602722 A	16-01-87 04-02-91 25-12-86
EP 431877 A	12-06-91	FR 2655266 A AT 112961 T AU 629071 B AU 6770490 A CA 2031066 A DE 69013473 D DE 69013473 T ES 2062417 T JP 4145016 A US 5229134 A	07-06-91 15-11-94 24-09-92 27-06-91 06-06-91 24-11-94 16-03-95 16-12-94 19-05-92 20-07-93
EP 655240 A	31-05-95	US 5500227 A AU 678859 B AU 7885594 A CA 2136411 A FI 945502 A HU 70416 A JP 7252140 A NO 944470 A ZA 9408677 A	19-03-96 12-06-97 08-06-95 24-05-95 24-05-95 30-10-95 03-10-95 24-05-95 04-07-95
US 5229131 A	20-07-93	NONE	
EP 396425 A	07-11-90	US 5122384 A US 5133974 A AT 128863 T AU 635021 B AU 5470390 A CA 2016039 A DE 69022876 D DE 69022876 T ES 2080796 T US 5296232 A US 5445829 A	16-06-92 28-07-92 15-10-95 11-03-93 08-11-90 05-11-90 16-11-95 02-05-96 16-02-96 22-03-94 29-08-95
EP 0502642 A	09-09-92	AU 650949 B	07-07-94

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/05234

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0502642 A		AU 1118092 A	10-09-92
		GB 2253348 A,B	09-09-92
		NZ 241686 A	23-12-93
		ZA 9201363 A	03-05-93

WO 9319741 A	14-10-93	AU 3949093 A	08-11-93

EP 0420459 A	03-04-91	US 5032405 A	16-07-91
		AU 6314790 A	11-04-91
		CA 2026283 A	28-03-91
		JP 3184920 A	12-08-91
